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Glioblastoma multiforme (GBM) is among the most incurable cancers. GBMs survival rate has not markedly
improved, despite new radical surgery protocols, the introduction of new anticancer drugs, new treatment
protocols, and advances in radiation techniques. The low efficacy of therapy, and short interval between re-
mission and recurrence, could be attributed to the resistance of a small fraction of tumorigenic cells to treatment.
The existence and importance of cancer stem cells (CSCs) is perceived by some as controversial. Experimental
evidences suggest that the presence of therapy-resistant glioblastoma stem cells (GSCs) could explain tumor
recurrence and metastasis. Some scientists, including most of the authors of this review, believe that GSCs are the
driving force behind GBM relapses, whereas others however, question the existence of GSCs. Evidence has ac-
cumulated indicating that non-tumorigenic cancer cells with high heterogeneity, could undergo reprogramming
and become GSCs. Hence, targeting GSCs as the “root cells” initiating malignancy has been proposed to eradicate
this devastating disease. Most standard treatments fail to completely eradicate GSCs, which can then cause the
recurrence of the disease. To effectively target GSCs, a comprehensive understanding of the biology of GSCs as
well as the mechanisms by which these cells survive during treatment and develop into new tumor, is urgently
needed. Herein, we provide an overview of the molecular features of GSCs, and elaborate how to facilitate their
detection and efficient targeting for therapeutic interventions. We also discuss GBM classifications based on the
molecular stem cell subtypes with a focus on potential therapeutic approaches.
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Introduction
Among the many types of primary tumors, glioblastoma multiforme
(GBM) is a highly aggressive and lethal cancer that is considered in-
curable. The current treatment is limited to gross total resection fol-
lowed by radical chemo- and radiotherapy. The chemotherapeutics that
have been used include alkylating agents such as nitrosoureas, which
induce cytotoxicity due to the formation of DNA cross-linking, and te-
mozolomide (TMZ), which promotes apoptosis via generation of single-
and double-strand breaks in DNA (Brandes et al., 2016).
Targeted therapies such as the administration of anti-angiogenic
agents, anti-epidermal growth factor receptor (EGFR), and phosphoi-
nositide 3-kinase (PI3K) inhibitors as an adjuvant for second line
treatment have also been used; however. These approaches have proven
to be only marginally effective, and the poor median survival of GBM
patients currently being 15 months, has not improved significantly
(Schwartzentruber et al., 2012). Despite advances in the current un-
derstanding of the molecular and cellular biology of GBM, treatment
strategies have not changed considerably. Moreover, the neurotoxicity
of the chemotherapy can induce the formation of secondary gliomas
(Dimov et al., 2011).
Other treatment complications have arisen owing to the stemness of
a rare subpopulation of tumor cells called glioblastoma stem cells
(GSCs) or tumor-initiating cells, which have stem cell characteristics
but are not necessarily derived from normal stem cells (Pointer et al.,
2014). They are able to self-renew, proliferate, and differentiate into
various cell types, which underlies the cellular heterogeneity in GBM.
GSCs give rise to new tumor cells after therapeutic eradication of the
bulk of the tumor (Chen et al., 2012). Although the concept of cancer
stem cells (CSCs) is controversial for some types of cancer, accumu-
lating evidence supports this concept, suggesting that GSCs may be a
primary contributing factor for tumor recurrence (Akbari-Birgani et al.,
2016; Farahani et al., 2014; Hombach-Klonisch et al., 2017; Wasik
et al., 2014). Indeed, GSCs harbor capacities for self-renewal, differ-
entiation, and plasticity, as well as increased chemo- and radio-
resistance (Ahmad and Amiji, 2017; Dey et al., 2010). The mechanisms
underlying drug resistance include, drug metabolic inactivation, in-
hibition of pro-drug to bioactive drug conversion, increased double
strand DNA repair, decreased drug influx and enhanced drug efflux.
Energy-dependent drug efflux lowers intracellular drug concentration.
This mechanism mostly operates via increased expression of the ATP-
binding cassette super family (ABC) of transporters (Hiddingh et al.,
2014). ABC transporters are commonly ovexpressed in GSC, in parti-
cular the ABCG2 (Wee et al., 2016). Many novel approaches have been
tested to achieve effective tumor cell targeted therapy. For example,
variety of drugs coupled to nano-vehicles have been employed to target
specific intra-cellular compartments to enhance tumor cell drug sensi-
tivity. For more details, see reviews (Bar-Zeev et al., 2017; Li et al.,
2016; Livney and Assaraf, 2013).
High expression of aldehyde dehydrogenase-I by GSCs is another
mechanism underlying GSC chemoresistance. Aldehyde dehydrogenase
detoxifies alkylating agents and reduces their reactivity by converting
drugs’ aldehyde groups into carboxylic acid. O6 –methyl-guanine DNA-
methyl transferase (MGMT), a detoxifier enzyme, is also considered to
contribute to chemoresistance (Safa et al., 2015; Soehngen et al., 2014).
Finally, high mobility group protein A2 (HMGA2), which is a structural
chromatin protein, is overexpressed in GSCs (Yi et al., 2016). These are
the most typically discussed topics in the literature. Indeed, GSCs have
recently been identified as potential therapeutic targets owing to their
roles in tumor initiation and recurrence (McCord et al., 2009; Zhou
et al., 2015b). Moreover, glioblastoma tumors exhibit proliferative and
hyper-angiogenic phenotypes that can vary substantially depending on
patient age and the extent of necrosis and hemorrhage (Barajas et al.,
2015; Burger et al., 1985). In the present review, we discuss GBM
classifications based on the molecular stem cell subtypes with a focus
on potential therapeutic approaches.
Characterization and isolation of GSCs
For characterization of CSCs, technologies such as fluorescence ac-
tivated cell sorter (FACS) (Ablett et al., 2012; Witt et al., 2016), and
magnetic activated cell sorting (MACS) (Torre-Healy et al., 2017) pro-
vide data for identification of single CSCs among cell populations.
These technologies take advantage of cellular granularity (FACS only),
size, and expression of well-defined surface markers (Hasmim et al.,
2016; Prestegarden et al., 2010). CD133, CD44, and CD24 are the most
common markers used as stemness identification tools, although several
studies have not confirmed their reproducibility and accuracy owing to
the genetic heterogeneity of CSCs (Dantas-Barbosa et al., 2015;
Hiddingh et al., 2014). Furthermore, microenvironmental signals in the
in vivo niches or during in vitro isolation and cultivation impose epi-
genetic changes, and variations in CSC phenotypes are also possible.
Consequently, there are many challenges that still need to be overcome.
To isolate and identify GSCs, specific and precise criteria are
needed. Singh et al., described appropriate methods for GSCs char-
acterization based on the functional properties of isolated GSCs.
Additionally, neurosphere assays can be applied to assess GSC pro-
liferation in vitro (Lathia and Liu, 2017; Singh et al., 2003). In this
approach, researchers cultivate cells in an appropriate concentration of
growth factors, and the frequencies of GSCs in tumors can be de-
termined (Lathia and Liu, 2017; Singh et al., 2004). Another approach
to identify GSCs is the use of specific surface markers to define sub-
populations within the tumor that are lineage-specific. For instance, the
aberrantly reactivated EGFR pathway, which causes genetic alteration,
has been detected in GBM (Flavahan et al., 2016) and results in EGFR
promoter alterations which facilitate EGFR overexpression (Erfani
et al., 2015; Iacopino et al., 2014). Recently, Erfani et al, developed a
method for the isolation of the EGFR+population of tumor cells in
which fluorescence-activated cell sorting is used, to select EGFR+ cells
based on their affinities towards EGF ligands. This further allowed the
determination that these cells displayed stemness properties by the
functional characterization including a highly proliferative neuro-
sphere, tri-lineage differentiation, as well as the expression of Sox2 and
nestin (Erfani et al., 2015) The most common GSC surface markers are
listed in Table 1.
GSC tumor microenvironment –the GBM niche
Researchers have started to focus on determining the origin and
identity of cells that induce the development of GBM and/or promote
metastasis and relapse. Several hypotheses have been proposed, in-
cluding dedifferentiation of ordinary neural cells, transformation of
undifferentiated precursor cells, and proliferation of neural stem cells
(NSCs) (Friedmann-Morvinski and Verma, 2014). According to these
hypotheses, when genetic mutations in oncogenes accumulate in
normal brain cells, dedifferentiation (a process similar to reprogram-
ming) may occur, or accumulation of genetic mutations in NSCs may
cause the NSCs to form cancer cells (Campos et al., 2016). The nature
and properties of stem cell niche is an important factor in determining
the fate of cancer stem cells (Farahani et al., 2014; Plaks et al., 2015).
In the adult mammalian brain, two neurogenic niches have been
identified: the subventricular zone (SVZ) located in the forebrain lateral
ventricle, and the sub-granular zone (SGZ) located in the hippocampus
in the dentate gyrus. Stem cells in both the quiescent and active mitotic
states reside in these two regions (Bayin et al., 2015). The tumor niche
can be divided into three distinct areas, including the perivascular
niche, which is characterized by non-malignant cells such as reactive
astrocytes, fibroblasts, pericytes, neural progenitor cells, and a variety
of immune cells, as well as malignant cells, including GSCs and tumor
cells surrounding disorganized blood vessels (Hambardzumyan and
Bergers, 2015). The interactions among these cells promote GSC sur-
vival and growth. Angiogenic factors, including vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF), and platelet-
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derived growth factor (PDGF), are important mediators of angiogenesis,
which affect the oxygen supply to the tumor. These angiogenic factors
may be produced by the tumor, especially under hypoxic conditions,
and could facilitate the formation of the tumor blood vessels (Calabrese
et al., 2007; Farahani et al., 2014; Plaks et al., 2015). Furthermore,
VEGF causes pericytes to separate from each other and the vascular
basement membrane to be disrupted. The specific role of VEGF in
pericyte disintegration leads to the formation of abnormal and leaky
blood vessels, which are enlarged and vulnerable to hemorrhage. This
phenomenon is phenotypically similar to the process in kidney glo-
meruli, called glomeruloid microvascular proliferation (GMP), and is a
hallmark of GBM (Dvorak, 2015). The leakiness of the GBM vessels has
severe consequences on the blood brain barrier (BBB) and disrupts its
firm structure (Abbott, 2013).
Following BBB disruption, tumor-derived chemokines/cytokines
attract immunomodulatory cells, which can enter the brain and secrete
more angiogenic factors, while suppressing immune function. The in-
teraction among these factors, tumor cells, and GSCs results in tumor
progression (Hambardzumyan and Bergers, 2015). The major popula-
tions of cells involved in this process at the tumor niche are monocytes,
myeloid-derived suppressor cells (MDSCs) (Kohanbash and Okada,
2012), and neutrophils (Bergers and Song, 2005; Feng et al., 2015;
Liang et al., 2014). Moreover, tumor-associated macrophages (TAM)s
are common infiltrating cells in the perivascular niche adjacent to GSCs
(Mantovani et al., 2002; Zhou et al., 2015a). These cells promote
neovascularization by producing heme oxygenase-1 (HO-1) and thy-
midine phosphorylase (TP), which are strongly associated with neo-
angiogenesis (Hirano et al., 2001). High expression of chemo-attrac-
tants by TAMs, including VEGF, interleukin (IL)-6, IL-1β, colony sti-
mulating factor (CSF), and stromal cell-derived factor 1α (SDF1α), re-
sults in recruitment of polarized macrophages and monocytes. This
generates an immunosuppressive phenotype and facilitates tumor pro-
gression. TAMs can also induce matrix metalloproteinase 9 (MMP9)
expression by releasing transforming growth factor-β (TGF-β), which
further promotes GSC proliferation (Badie and Schartner, 2001;
Hambardzumyan et al., 2016). In turn, GSCs can release periostin in the
aforementioned niche, which acts as another chemoattractant for TAMs
(Zhou et al., 2015a).
The perinecrotic or hypoxic niche, which can be identified by cells
around the necrosis center (i.e., irregular architecture, blind ends, ab-
sence of smooth muscles and high permeability), is created from in-
efficient blood supply, which causes hypoxia, subsequently induces
pseudo-palisading necrosis, and is an important regulator of tumor
growth, cell maintenance, stemness induction, and immune surveil-
lance (Ishii et al., 2016; Semenza, 2010; Soeda et al., 2009)
Hypoxia-inducible factors (HIF1 and HIF2) are the main proteins
upregulated in response to low oxygen tension. They are strong in-
ducers of VEGF and IL-8, which promote angiogenesis and invasion
(Brat, 2011; Filatova et al., 2013; Schito and Semenza, 2016; Zagzag
et al., 2006) and also activate genes involved in dedifferentiation and
self-renewal. Some studies have found GSCs as an enriched population
in the hypoxic niche (Seidel et al., 2010; Uribe et al., 2017). Indeed,
hypoxia induces stemness characteristics, which can be measured by
increased expression of CD133 and other GSC markers (Bar et al., 2010;
Silver and Lathia, 2017; Soeda et al., 2009). Hence, GSCs and tumor
cells may be maintained in the hypoxic niche, even after chemo/
radiotherapy, and the death of cells in the necrotic area results in re-
lease of pro-inflammatory signals, which converts inflammatory cells to
immunosuppressive cells (Casazza et al., 2013; Qian and Pollard, 2010;
Rivera and Bergers, 2015). These events cause the cells to lose function
and induce angiogenesis. Furthermore, hypoxia stimulates the differ-
entiation of GSCs into endothelial cells, which could explain the growth
of tumors and GSCs in a direction from the necrotic area towards the
neovascular region (Soda et al., 2011).
The invasive niche for GBM has also been identified. GBM tumor
cells have the unique ability to use normal blood vessels to migrate, andTa
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they invade the normal brain parenchyma in this manner (Cuddapah
et al., 2014). Complete deletion of MMP2 and MMP9 can enhance
perivascular invasiveness and reduce angiogenesis, in contrast to the
aforementioned niches (Du et al., 2008; Silver and Lathia, 2017). As-
trocytes are the key cells in this niche. Exchange of ions and metabolites
between blood vessels and the brain occurs via direct contact between
astrocyte-end feet and pericytes and/or endothelial cells (Mathiisen
et al., 2010; Silver and Lathia, 2017). The invasive niche of glioma cells
can also induce astrocyte proliferation and migration by paracrine in-
teraction. These reactive astrocytes can release connective tissue
growth factor (CTGF), which binds to tropomyosin receptor kinase type
A (TRKA) and integrin-1β that are located on the surface of GSCs. This
leads to tumor cell infiltration via induction of zinc finger E-box binding
homeobox-1 (ZEB1), a transcription factor involved in the epithelial-
mesenchymal transition (EMT) (Abbott, 2013; Edwards et al., 2011).
Studies have shown that astrocytes, which are reactive to growth
factors, cytokines, and metabolites, express sonic hedgehog (SHH); SHH
is attached to the membrane protein Patch1, leading to activation of
GLI and promoting stemness properties. Thus, astrocytes are important
cells in the maintenance of GSCs and invasiveness of tumors (Becher
et al., 2008). On the basis of these findings, larger tumors are expected
to have expanded invasive niches, resulting in induction of neo-angio-
genesis through hypoxia.
Genetic events involved in GSC biology
To obtain basic knowledge for targeting GSCs and efficient treat-
ment of GBM, the genetic and epigenetic alterations in these cells must
be well defined, and the molecular pathways and cellular interactions
between GSCs and the tumor microenvironment as well as normal cells
must be evaluated. Seventy-four genetic mutations have been detected
using accessible data in The Cancer Genome Atlas (TCGA) via the c bio
portal (Table 2). This database has been used to categorize mutations,
and the most frequently identified signaling pathways are discussed
below, and listed in Table 4.
The most common pathways involved in maintenance of GSCs
Notch signaling pathway
Notch signaling plays important roles in cell fate, proliferation and
migration, also it is involved in maintaining cellular quiescence and
regulating neural (NSC) differentiation (Saito et al., 2017). The clea-
vage of notch receptor by γ-secretase by the jagged family or delta li-
gands binding, leads to the translocation of Notch intracellular domain
(NICD) to the nucleolus; this results in the formation a complex with
RBPJ and MAML in the nucleus and activation of the hairy and en-
hancer of split (HES) and HEY genes, thereby promoting the
Table 2
Genes commonly mutated in GBM.
Gene Function Expression status Reference
EGFR Regulates processes involved in cell growth, division, and
survival
Gain of function/amplification (Mazzoleni et al., 2010)
IDH1 Produces NADPH Gain of function/amplification (Cohen et al., 2013)
PDGFRA Regulates processes involved in cell growth, division, and
survival
Gain of function/amplification (Furnari et al., 2015; Koschmann et al., 2016; McLendon et al.,
2008)
HDM2 Regulates processes involved in cell growth, division, and
survival
Gain of function/amplification (de Toledo et al., 2000; Lathia and Liu, 2017; Noushmehr et al.,
2010)
PIK3CA Regulates processes involved in cell growth, division, and
survival
Gain of function/amplification (Gallia et al., 2006; Zhao et al., 2017)
TERT Induces EGFR expression/involved in cell renewal Gain of function/amplification (Beck et al., 2011)
PIK3R1 Regulates processes involved in cell growth, division, and
survival
Gain of function/amplification (McLendon et al., 2008; Zhao et al., 2017)
PTEN Regulates cell signaling involved in cell proliferation and
survival
Loss of function/deletion (Benitez et al., 2017; Zheng et al., 2008)
TP53 Check point protein involved in apoptosis Loss of function/deletion (Daniele et al., 2014)
CDKN2A Cell cycle regulation/retinoblastoma activation Loss of function/deletion (Faiq et al., 2015; Parsons et al., 2008)
NF1 Regulates cell signaling involved in cell proliferation and
survival
Loss of function/deletion (Verhaak et al., 2010)
ATRX Regulates cell division Loss of function /deletion (Cottini et al., 2013; Schwartzentruber et al., 2012)
RB Regulation of cell cycle Loss of function/deletion (Cenciarelli et al., 2016)
Fig. 1. TCGA analysis of PcGs in GBM patients. Due to the lack of a GSC database, the diagram shows PcG alterations with special consideration of the occurrence
frequency and type of mutation.
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maintenance of multipotency (Bayin et al., 2017; Dantas-Barbosa et al.,
2015).
CD133-positive GSCs overexpress Notch signaling pathway activa-
tors, including inhibitor of differentiation 4 (ID4) and a cellular cha-
peron; fatty acid-binding protein 7 (FABP7), which directly affect radial
ganglion cell (RGC) migration. High expression of these genes promotes
infiltrating potential of GBM tumors (Kaloshi et al., 2007); thus, the
Notch signaling pathway is thought to promote migration. The activa-
tion mechanisms of oncogenic signaling in GSCs by Notch, remain
unclear, however it had been shown that an extracellular matrix protein
Tenascin-C, increased Notch activation in GSCs (Sarkar et al., 2017).
Notch signaling activation is also involved in maintaining the stemness
of GSCs, and determining glial cell fate. Thus, inactivation of this
pathway may be an effective method for blocking GSCs and limiting
tumor growth.
Sonic hedgehog (SHH)/glioma-associated oncogene (GLI) signaling pathway
During embryonic development, SHH plays a critical role in orga-
nogenesis and especially neural progenitor regulation. However, this is
not the case in quiescent adult tissues, with the exception of repair and
tissue maintenance. Hence, this is an important pathway affecting the
self-renewal and tumorigenicity of GSCs (Clement et al., 2007;
Honorato et al., 2018). The majority of GSCs have activated the SHH/
GLI-pathway and it also causes the up-regulation of drug efflux P-gly-
coprotein (ABCB1), ABCG2/BCRP, ABCC1/MRP1 MGMT, BMI,
(Hombach-Klonisch et al., 2017; Shahi et al., 2016). Recently, studies
have shown that SHH/GLI activity is crucial for Nanog regulation, and
Fig. 2. Molecular interactions among GSCs and aforementioned factors. A brief graphical explanation is provided for the intracellular and extracellular factors that
promote or inhibit stemness.
Table 3
miRNAs involved in the regulation of GBM fate.
miRNA Gene targeted Changed Expression in
GBM
Function Reference
miR-218 BMI1, LEF1, IKBKB, ECOP, CDK6 downregulated Inhibits glioma stem-like cells (Liu et al., 2012; Mathew et al., 2014; Zhang et al., 2011)
miR-107 Notch-2, SLLA4, CDK6 downregulated Downregulation of Nestin and CD133 (Chen et al., 2013; He et al., 2013)
miR-128 P70S6K1, SUZ12, BMI1, PDGFRα,
EGFR, E2F3a, WEE1, MSI1
downregulated Suppresses PRC activity, early events
in gliomagenesis
(Ciafre et al., 2005; Papagiannakopoulos et al., 2012; Rooj
et al., 2016; Zhang et al., 2009)
miR-134 KRAS, STAT5B downregulated Stimulates differentiation (Zhang et al., 2014)
miR-153 BCL2, MCL1, IRS1 downregulated Impairs self-renewal and
differentiation
(Xu et al., 2011; Zhao et al., 2013)
miR-203 PLD2, SNAI downregulated Inhibits stemness and glioma cell
migration
(Deng et al., 2016; Liao et al., 2015)
miR-let-7 NRAS, KRAS, CCND1 downregulated Possible anti-tumorigenic effects (Guo et al., 2013; Wang et al., 2013)
miR-124 SNAI1, PIM3, NRAS, SOS downregulated Decreases self-renewal and migration (Lv and Yang, 2013; Xia et al., 2012)
miR-34 MET, NOTCH1, NOTCH2, downregulated Induces apoptosis and inhibit invasion (Guessous et al., 2010; Li et al., 2009)
miR-145 Sox2 downregulated Contributes to silencing of c-Myc (Speranza et al., 2012)
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binding of SHH/GLI1/GLI2 to the Nanog promoter leads to activation of
Nanog expression. The transcription factor Nanog is one of the ‘master
regulators’ of the expression of several stemness factors. Conversely,
p53 downregulates Nanog expression by decreasing GLI1 expression
and activity. Furthermore, loss of p53 leads to activation of SHH sig-
naling, upregulation of Nanog, and maintenance of stemness properties
(Abou-Antoun et al., 2017; Ma et al., 2017; Zbinden et al., 2010). In
contrast, bone morphogenic protein (BMP), which may also act as a
growth factor and have pro-differentiation activities in stem cells, is
downregulated by GLI. Piccirillo et al., showed that this pathway
blocked the proliferation of GSCs (Piccirillo et al., 2006; Shahi et al.,
2016). Furthermore, inhibition of SHH could potentiate the therapeutic
effect of TMZ, one of the key drugs employed to treat glioblastoma.
Hence, the aforementioned studies affirm the contribution of this
pathway to GSCs chemoresistance and its targeting could potentially
increase chemotherapy efficacy (Honorato et al., 2018).
The Wnt/β-catenin signaling pathway
During CNS development, the Wnt signaling pathway is a crucial
player in self-renewal, differentiation, and NSC development specifi-
cally in axis patterning and the differentiation of posterior and interior
structure of CNS. (Kalani et al., 2008; Zuccarini et al., 2018). However,
aberrant activation of this pathway in the CNS leads to transformation
into brain tumors. The regulatory association between the Wnt pathway
and maintenance of GSCs involves genetic and epigenetic mechanisms
(Pulvirenti et al., 2011). With regard to genetic regulation, over-
expression of pleomorphic adenoma gene-like2 (PLAGL2) results in
upregulation of Wnt components such as frizzled (FZD) 2, FZD9, and
Wnt6, thereby activating the canonical Wnt pathway (Zheng et al.,
2010; Zuccarini et al., 2018). The other genetic event affecting Wnt is
FoxM1, which directly binds to the Sox2 promoter and induces stem-
ness programming and maintenance of GSCs (Lee et al., 2015).
Epigenetic factors affect Wnt signaling; the transmembrane protein
Evi, which is overexpressed in GBM, is regulated via epigenetic me-
chanisms and alters the canonical and non-canonical Wnt pathways
(Ahmad and Amiji, 2017; Augustin et al., 2012; Bartscherer et al.,
2006). Moreover, a Wnt family member; Wnt5A promotes endothelial
differentiation of GSCs which is associated with neovascularization,
hence providing environment that facilitates tumor cell growth and
invasion (Binda et al., 2017; Hu et al., 2016).
These studies have shown that canonical and non-canonical Wnt
signaling pathways are involved in maintenance and gliomagenesis of
GSCs. Furthermore, Wnt signaling induces TMZ resistance through
promotion of O6-methylguanine-DNA methyltransferase (MGMT) ex-
pression, which protects the genome from anticancer therapeutics like
TMZ, that act as alkylating agents (Lee et al., 2016; Wickström et al.,
2015). Broad and unspecific targeting of the Wnt signaling pathway is
not a viable option because of its key role in the aforementioned phy-
siologic functions in the brain and in other tissues and organs. The
blockade of such a crucial signaling system, which controls vital func-
tions will certainly cause serious side effects in patients. Though, it
would be essential to design strategies based on targeting the Wnt axis
at the tumor level (Zuccarini et al., 2018).
Epigenetic changes in GSCs
Epigenetic heterogeneity is involved in regulation of GSCs.
Epigenetic mechanisms are considered a dynamic interface between
physical, social and metabolic signals of the external world, allowing
changes in gene expression in response to the environment (Herman
and Baylin, 2003). Indeed, GBM harbors not only genetic- but also
epigenetic alterations, which in concert regulate cancer cell gene ex-
pression (Mack et al., 2016).
Epigenetic changes may involve: (i) DNA methylation especially
within gene-promotor area (CpG islands), hence affecting geneTa
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expression. Specifically, promoter hypermethylation (addition of me-
thyl groups to cytosine residues in DNA) results in gene silencing.
Hypermethylation of tumor-suppressor genes, such as TP53, can pro-
mote cancer development (Noushmehr et al., 2010). Conversely, hy-
pomethylation (decreased methylation) causes activation of genes that
are normally silenced or suppressed, such as oncogenes (Feinberg and
Vogelstein, 1983; Noushmehr et al., 2010). (ii) Post-translational
modifications of histones, i.e., methylation, acetylation, phosphoryla-
tion, sumoylation, and ubiquitylation, affect the chromatin architecture
and result in epigenetic changes in the regions around enhancers,
promoters, and other regulatory elements. Mutations in the histone
modification pathway can promote and enhance GBM formation
(Tessarz and Kouzarides, 2014). (iii) Polycomb group proteins (PcGs)
play a crucial role in embryonic development and can cause gene si-
lencing through chromatin remodeling (Fig. 1). Dysregulation of these
proteins leads to tumor progression, invasion, and metastasis (Koppens
and Van Lohuizen, 2016). The TCGA database, reveals a numbers of
PcGs with altered expression in GBM versus the normal brain as shown
in Fig. 2. Among the listed proteins, BMI1, one of the members of
polycomb repressive complex1 (PRC1), prevents GSCs from differ-
entiating into mature neurons and also inhibits apoptosis (Abdouh
et al., 2009). EZH2, a component of the polycomb repressive complex2
(PRC2), is also thought to be involved in sustaining GSCs through the
activation of STAT3 (Kim et al., 2013). Owing to intricate interactions
among these proteins, they are thought to also be involved in inducing
GBM progression and invasion. (iv) Modifications in microRNAs
(miRNA), which are non-coding functional RNAs that have crucial ef-
fects on post-transcriptional regulation (Table 3). miRNA expression is
greatly altered in GSCs versus the normal brain (Nagarajan and
Costello, 2009). Moller et al., demonstrated altered expression of 351
miRNAs in GBM, with 256 overexpressed and 95 under-expressed
(Møller et al., 2013).
Conclusions and perspectives regarding therapeutic agents for
eradication of GSCs
Despite major advances in research, treatment of GBM continues to
be a major challenge. Surgical resection followed by radical chemor-
adiotherapy is a standard treatment protocol in patients with GBM
(Tome-Garcia et al., 2017). However, the only benefit that these
treatments can achieve is shrinking the tumor size by killing active
cancer cells. Tumor metastasis or recurrence is common after such
treatments owing to molecular heterogeneity and the unique tumor
microenvironment in GMB (McCord et al., 2009). Therefore, it is crucial
to design strategies that focus on targeting GSCs and their micro-
environment components to eradicate GSCs in combination with tra-
ditional therapies, which may lead to more effective treatment. Other
available treatment approaches include specific chemotherapeutic
agents, immunotherapies, radiotherapies, gene therapies, and induction
of GSC differentiation to normal cells; these treatment modalities may
have applications in the targeting of GSCs with the goal of eradicating
minimal residual disease and blocking tumor recurrence (Cho et al.,
2013).
Currently, many studies are underway to target GSCs for more ef-
fective treatment. For example, Thanasupawat et al., tested a small
molecule inhibitor, dovitinib (Dov; TK1258, CHIR258) (Thanasupawat
et al., 2017). Dov is a benzimidazole-quinolinone compound that acts as
a receptor tyrosine kinase inhibitor and down-regulates HMGA2. Con-
sidering the special function of HMGA2 protein in self-renewal, its
down-regulation should reduce the size of GB tumors. Dov also causes
reduced expression of MGMT, which is an important enzyme that plays
an important role in the repair of DNA damage caused by the alkylating
activity of TMZ (as shown above), and is a potential chemoresistance
determinant. Dov damages DNA by its localization in the minor groove,
and it targets topoisomerase I and II. Combinatorial treatment of TMZ
with Dov enhances DNA damage and apoptosis in GB cells
(Thanasupawat et al., 2017). The pathway blockers demonstrated in
Fig. 3 are other examples of these stemness-targeted drugs. Selected,
Fig. 3. Schematic diagram of the signaling pathways
most involved in GSC maintenance and their compo-
nents, which are already used as targets of most
commonly used drugs. Wnt signaling: Binding of wnt
proteins with the Frizzled and low density lipoprotein
receptor-related protein/ɑ2 macroglobulin receptor
(LRP) families as their receptor results in dis-
assembling of Axin, adenomatous polyposis coli (APC),
and formation of the GSK3β complex through stabili-
zation of βcatenin. This produces a signal to the β-
catenin to migrate to the nucleus and make a con-
nection with T cell factor (TCF) to activate their target
gene, which is involved in stem cell maintenance.
Celecoxib, a member of the non-steroidal anti-in-
flammatory drug (NSAID) family, targets the cycloox-
ygenase2 (COX2) gene and XAV939 and SEN461, two
small molecules that have shown therapeutic promise
for the treatment of Wnt-induced gliomas by stabi-
lizing Axin, such that the amount of cytoplasmic
phosphorylated β-catenin increases and then β-catenin
cannot move to the nucleolus. SHH pathway: Binding
of HH ligands to 12 transmembrane patched homo-
logue1 (PTCH1) causes 7-transmembrane protein
smoothened homologue (SMO) release. Thus, GLI is
activated via a multistep process and moves to the
nucleolus to induce transcription and regulate genes
while stimulating cell proliferation, self-renewal, and
chemoresistance. Vismodegib binds to SMO and blocks the rest of the pathway. Notch pathway: The interaction between notch ligand and the notch receptor initiates
Notch signaling, which proceeds by the sequential cleavage of Notch; therefore, Notch intracellular domain (NICD) is released from the membrane and moves toward
the nucleolus. There, it forms a transcriptional activating complex with the nuclear transcription factor CSL and the co activator (CoA). This complex induces target
genes involved in self-renewal and chemoresistance. Tarextumab is a monoclonal antibody (Ab) that targets Notch receptors and blocks the whole pathway. Blockade
of this pathway appears to restrict self-renewal.
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potential targets for GMB-therapy have been listed in Table 4.
Salinomycin is another potentially promising experimental drug
that preferentially kills GSCs as well as other types of CSCs
(Jangamreddy et al., 2013, 2015; Xipell et al., 2016). While phase I
clinical trials testing the potential use of salinomycin in glioblastoma
yet await to be published, the drug and its derivatives, are currently
being intensively explored as an anti-CSCs agent for several types of
malignancies.
In the current review, we highlighted the molecular markers that
can be utilized to isolate GSCs from normal stem cells. These promising
therapeutic targets may afford a systematic, well-organized approach
for cancer treatment and prevent further exposure of patients to the
severe side effects of chemoradiotherapies and more invasive ap-
proaches. Further laboratory and clinical investigations are needed to
identify the appropriate selection of targets for promising treatments.
Acknowledgements
The authors would like to acknowledge Mr. Hamidreza Abolkheir
and Mr. Javad Firouzi, scientists researchers at the Royan Institute, for
their support for the completion of this study. Saeid Ghavami has been
supported by a Health Science Centre General Operating Grant and
Research Manitoba New Investigator Operating Grant. MJŁ kindly ac-
knowledges the support from NCN grant #: 2016/21/B/NZ1/02812,
the supported by LE STUDIUM Institute for Advanced Studies (region
Centre-Val de Loire, France) through its Smart Loire Valley General
Program, co-funded by the Marie Sklodowska-Curie Actions, grant #
665790. Marzieh Ebrahimi has been supported by Iranian council for
stem cell sciences and technologies, grant# Rep 218 and Royan in-
stitute, grant# 94000197.
References
Abbott, N.J., 2013. Blood–brain barrier structure and function and the challenges for CNS
drug delivery. J. Inherit. Metab. Dis. 36, 437–449.
Abdouh, M., Facchino, S., Chatoo, W., Balasingam, V., Ferreira, J., Bernier, G., 2009.
BMI1 sustains human glioblastoma multiforme stem cell renewal. J. Neurosci. 29,
8884–8896.
Ablett, M.P., Singh, J.K., Clarke, R.B., 2012. Stem cells in breast tumours: are they ready
for the clinic? Eur. J. Cancer 48, 2104–2116.
Abou-Antoun, T.J., Hale, J.S., Lathia, J.D., Dombrowski, S.M., 2017. Brain cancer stem
cells in adults and children: cell biology and therapeutic implications.
Neurotherapeutics 14, 372–384.
Ahmad, G., Amiji, M.M., 2017. Cancer stem cell-targeted therapeutics and delivery
strategies. Expert Opin. Drug Deliv. 14, 997–1008.
Akbari-Birgani, S., Paranjothy, T., Zuse, A., Janikowski, T., Cieslar-Pobuda, A., Likus, W.,
Urasinska, E., Schweizer, F., Ghavami, S., Klonisch, T., Los, M.J., 2016. Cancer stem
cells, cancer-initiating cells and methods for their detection. Drug Discov. Today 21,
836–842.
Ariza, A., López, D., Mate, J.L., Isamat, M., Musulen, E., Pujol, M., Ley, A., Navas-palacios,
J., 1995. Role of CD44 in the invasiveness of glioblastoma multiforme and the
noninvasiveness of meningioma: an immunohistochemistry study. Hum. Pathol. 26,
1144–1147.
Augustin, I., Goidts, V., Bongers, A., Kerr, G., Vollert, G., Radlwimmer, B., Hartmann, C.,
Herold-Mende, C., Reifenberger, G., von Deimling, A., 2012. The Wnt secretion
protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol. Med. 4, 38–51.
Auvergne, R.M., Sim, F.J., Wang, S., Chandler-Militello, D., Burch, J., Al Fanek, Y., Davis,
D., Benraiss, A., Walter, K., Achanta, P., 2013. Transcriptional distinctions between
normal and glioma-derived A2B5+ progenitor cells identify a core set of genes
dysregulated at all stages of gliomagenesis. Cell Rep. 3, 2127.
Auvergne, R., Wu, C., Connell, A., Au, S., Cornwell, A., Osipovitch, M., Benraiss, A.,
Dangelmajer, S., Guerrero-Cazares, H., Quinones-Hinojosa, A., 2016. PAR1 inhibition
suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and
their derived gliomas in vivo. Oncogene 35, 3817.
Badie, B., Schartner, J., 2001. Role of microglia in glioma biology. Microsc. Res. Tech. 54,
106–113.
Bar, E.E., Lin, A., Mahairaki, V., Matsui, W., Eberhart, C.G., 2010. Hypoxia increases the
expression of stem-cell markers and promotes clonogenicity in glioblastoma neuro-
spheres. Am. J. Pathol. 177, 1491–1502.
Barajas Jr., R.F., Phillips, J.J., Vandenberg, S.R., McDermott, M.W., Berger, M.S., Dillon,
W.P., Cha, S., 2015. Pro-angiogenic cellular and genomic expression patterns within
glioblastoma influences dynamic susceptibility weighted perfusion MRI. Clin. Radiol.
70, 1087–1095.
Bartscherer, K., Pelte, N., Ingelfinger, D., Boutros, M., 2006. Secretion of Wnt ligands
requires Evi, a conserved transmembrane protein. Cell 125, 523–533.
Bar-Zeev, M., Livney, Y.D., Assaraf, Y.G., 2017. Targeted nanomedicine for cancer ther-
apeutics: towards precision medicine overcoming drug resistance. Drug Resist.
Updates 31, 15–30.
Bayin, N.S., Modrek, A.S., Placantonakis, D.G., 2015. Brain tumor stem cells. Molecular
Pathology of Nervous System Tumors. Springer, pp. 23–34.
Bayin, N.S., Frenster, J.D., Sen, R., Si, S., Modrek, A.S., Galifianakis, N., Dolgalev, I.,
Ortenzi, V., Illa-Bochaca, I., Khahera, A., Serrano, J., Chiriboga, L., Zagzag, D.,
Golfinos, J.G., Doyle, W., Tsirigos, A., Heguy, A., Chesler, M., Barcellos-Hoff, M.H.,
Snuderl, M., Placantonakis, D.G., 2017. Notch signaling regulates metabolic hetero-
geneity in glioblastoma stem cells. Oncotarget 8, 64932–64953.
Becher, O.J., Hambardzumyan, D., Fomchenko, E.I., Momota, H., Mainwaring, L., Bleau,
A.-M., Katz, A.M., Edgar, M., Kenney, A.M., Cordon-Cardo, C., 2008. Gli activity
correlates with tumor grade in platelet-derived growth factor–induced gliomas.
Cancer Res. 68, 2241–2249.
Beck, S., Jin, X., Sohn, Y.-W., Kim, J.-K., Kim, S.-H., Yin, J., Pian, X., Kim, S.-C., Nam, D.-
H., Choi, Y.-J., 2011. Telomerase activity-independent function of TERT allows
glioma cells to attain cancer stem cell characteristics by inducing EGFR expression.
Mol. Cells 31, 9–15.
Benitez, J.A., Ma, J., D’Antonio, M., Boyer, A., Camargo, M.F., Zanca, C., Kelly, S.,
Khodadadi-Jamayran, A., Jameson, N.M., Andersen, M., 2017. PTEN regulates glio-
blastoma oncogenesis through chromatin-associated complexes of DAXX and histone
H3. 3. Nat. Commun. 8, 15223.
Bergers, G., Song, S., 2005. The role of pericytes in blood-vessel formation and main-
tenance. Neurooncology 7, 452–464.
Binda, E., Visioli, A., Giani, F., Trivieri, N., Palumbo, O., Restelli, S., Dezi, F., Mazza, T.,
Fusilli, C., Legnani, F., 2017. Wnt5a drives an invasive phenotype in human glio-
blastoma stem-like cells. Cancer Res. 77, 996–1007.
Brandes, A.A., Bartolotti, M., Tosoni, A., Franceschi, E., 2016. Nitrosoureas in the man-
agement of malignant gliomas. Curr. Neurol. Neurosci. Rep. 16, 13.
Brat, D.J., 2011. Glioblastoma: biology, genetics, and behavior. American Society of
Clinical Oncology Educational book/ASCO. American Society of Clinical Oncology.
Meeting. pp. 102–107.
Burger, P.C., Vogel, F.S., Green, S.B., Strike, T.A., 1985. Glioblastoma multiforme and
anaplastic astrocytoma pathologic criteria and prognostic implications. Cancer 56,
1106–1111.
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., Hamner, B., Oh, E.Y.,
Gaber, M.W., Finklestein, D., Allen, M., 2007. A perivascular niche for brain tumor
stem cells. Cancer Cell 11, 69–82.
Campos, B., Olsen, L.R., Urup, T., Poulsen, H., 2016. A comprehensive profile of recurrent
glioblastoma. Oncogene 35, 5819–5825.
Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M.,
Deschoemaeker, S., Van Ginderachter, J.A., Tamagnone, L., Mazzone, M., 2013.
Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling
blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24,
695–709.
Cenciarelli, C., Marei, H.E., Felsani, A., Casalbore, P., Sica, G., Puglisi, M.A., Cameron,
A.J., Olivi, A., Mangiola, A., 2016. PDGFRα Depletion Attenuates Glioblastoma Stem
Cells Features By Modulation of STAT3, RB1 and Multiple Oncogenic Signals.
Chen, J., Li, Y., Yu, T.-S., McKay, R.M., Burns, D.K., Kernie, S.G., Parada, L.F., 2012. A
restricted cell population propagates glioblastoma growth after chemotherapy.
Nature 488, 522–526.
Chen, L., Chen, X.-R., Zhang, R., Li, P., Liu, Y., Yan, K., Jiang, X.-D., 2013. MicroRNA-107
inhibits glioma cell migration and invasion by modulating Notch2 expression. J.
Neurooncol. 112, 59–66.
Chen, H.-Y., Lin, L.-T., Wang, M.-L., Laurent, B., Hsu, C.-H., Pan, C.-M., Jiang, W.-R.,
Chen, P.-Y., Ma, H.-I., Chen, Y.-W., 2017. Musashi-1 enhances glioblastoma cell
migration and cytoskeletal dynamics through translational inhibition of Tensin3. Sci.
Rep. 7, 8710.
Cho, D.-Y., Lin, S.-Z., Yang, W.-K., Lee, H.-C., Hsu, D.-M., Lin, H.-L., Chen, C.-C., Liu, C.-L.,
Lee, W.-Y., Ho, L.-H., 2013. Targeting cancer stem cells for treatment of glioblastoma
multiforme. Cell Transplant. 22, 731–739.
Ciafre, S., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M.,
Maira, G., Croce, C., Farace, M., 2005. Extensive modulation of a set of microRNAs in
primary glioblastoma. Biochem. Biophys. Res. Commun. 334, 1351–1358.
Clement, V., Sanchez, P., De Tribolet, N., Radovanovic, I., i Altaba, A.R., 2007.
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-
renewal, and tumorigenicity. Curr. Biol. 17, 165–172.
Cohen, A.L., Holmen, S.L., Colman, H., 2013. IDH1 and IDH2 mutations in gliomas. Curr.
Neurol. Neurosci. Rep. 13, 345.
Cottini, F., Anderson, K.C., Tonon, G., 2013. Cancer Genomics: From Bench to
Personalized Medicine. Elsevier Inc.
Cuddapah, V.A., Robel, S., Watkins, S., Sontheimer, H., 2014. A neurocentric perspective
on glioma invasion. Nat. Rev. Neurosci. 15, 455–465.
Daniele, S., Taliani, S., Da Pozzo, E., Giacomelli, C., Costa, B., Trincavelli, M.L., Rossi, L.,
La Pietra, V., Barresi, E., Carotenuto, A., 2014. Apoptosis therapy in cancer: the first
single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci.
Rep. 4, 4749.
Dantas-Barbosa, C., Bergthold, G., Daudigeos-Dubus, E., Blockus, H., Boylan, J.F.,
Ferreira, C., Puget, S., Abely, M., Vassal, G., Grill, J., Geoerger, B., 2015. Inhibition of
the NOTCH pathway using gamma-secretase inhibitor RO4929097 has limited anti-
tumor activity in established glial tumors. Anticancer Drugs 26, 272–283.
De Robertis, A., Valensin, S., Rossi, M., Tunici, P., Verani, M., De Rosa, A., Giordano, C.,
Varrone, M., Nencini, A., Pratelli, C., 2013. Identification and characterization of a
small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol. Cancer Ther. 12,
1180–1189.
de Toledo, S.M., Azzam, E.I., Dahlberg, W.K., Gooding, T.B., Little, J.B., 2000. ATM
F. Sharifzad, et al. Drug Resistance Updates 42 (2019) 35–45
42
complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent
manner in normal and tumor human cells exposed to ionizing radiation. Oncogene
19, 6185.
Deng, Y., Zhu, G., Luo, H., Zhao, S., 2016. MicroRNA-203 As a stemness inhibitor of
glioblastoma stem cells. Mol. Cells 39, 619.
Dey, M., Ulasov, I.V., Lesniak, M.S., 2010. Virotherapy against malignant glioma stem
cells. Cancer Lett. 289, 1–10.
Dimov, I., Tasic-Dimov, D., Conic, I., Stefanovic, V., 2011. Glioblastoma multiforme stem
cells. Sci. World J. 11, 930–958.
Dragu, D.L., Necula, L.G., Bleotu, C., Diaconu, C.C., Chivu-Economescu, M., 2015.
Therapies targeting cancer stem cells: current trends and future challenges. World J.
Stem Cells 7, 1185.
Du, R., Petritsch, C., Lu, K., Liu, P., Haller, A., Ganss, R., Song, H., Vandenberg, S.,
Bergers, G., 2008. Matrix metalloproteinase-2 regulates vascular patterning and
growth affecting tumor cell survival and invasion in GBM. Neurooncology 10,
254–264.
Dvorak, H.F., 2015. Tumors: wounds that do not heal—redux. Cancer Immunol. Res. 3,
1–11.
Edwards, L.A., Woolard, K., Son, M.J., Li, A., Lee, J., Ene, C., Mantey, S.A., Maric, D.,
Song, H., Belova, G., 2011. Effect of brain-and tumor-derived connective tissue
growth factor on glioma invasion. J. Natl. Cancer Inst. 103, 1162–1178.
Erfani, P., Tome-Garcia, J., Canoll, P., Doetsch, F., Tsankova, N.M., 2015. EGFR promoter
exhibits dynamic histone modifications and binding of ASH2L and P300 in human
germinal matrix and gliomas. Epigenetics 10, 496–507.
Faiq, N., Chmielecki, J., Goldberg, M., Stephens, P., Kurzrock, R., Kesari, S., Piccioni,
D.E., 2015. Analysis of BRAF Alterations and Molecular Profiling in Glioblastoma and
Astrocytoma. American Society of Clinical Oncology.
Farahani, E., Patra, H.K., Jangamreddy, J.R., Rashedi, I., Kawalec, M., Rao Pariti, R.K.,
Batakis, P., Wiechec, E., 2014. Cell adhesion molecules and their relation to (cancer)
cell stemness. Carcinogenesis 35, 747–759.
Feinberg, A.P., Vogelstein, B., 1983. Hypomethylation of ras oncogenes in primary human
cancers. Biochem. Biophys. Res. Commun. 111, 47–54.
Feng, X., Szulzewsky, F., Yerevanian, A., Chen, Z., Heinzmann, D., Rasmussen, R.D.,
Alvarez-Garcia, V., Kim, Y., Wang, B., Tamagno, I., 2015. Loss of CX3CR1 increases
accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget 6,
15077.
Filatova, A., Acker, T., Garvalov, B.K., 2013. The cancer stem cell niche (s): the crosstalk
between glioma stem cells and their microenvironment. Biochim. Biophys. Acta
(BBA)-Gen. Subjects 1830, 2496–2508.
Flavahan, W.A., Drier, Y., Liau, B.B., Gillespie, S.M., Venteicher, A.S., Stemmer-
Rachamimov, A.O., Suva, M.L., Bernstein, B.E., 2016. Insulator dysfunction and on-
cogene activation in IDH mutant gliomas. Nature 529, 110–114.
Friedmann-Morvinski, D., Verma, I.M., 2014. Dedifferentiation and reprogramming:
origins of cancer stem cells. EMBO Rep., e201338254.
Furnari, F.B., Cloughesy, T.F., Cavenee, W.K., Mischel, P.S., 2015. Heterogeneity of epi-
dermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer
15, 302.
Gallia, G.L., Rand, V., Siu, I.-M., Eberhart, C.G., James, C.D., Marie, S.K., Oba-Shinjo,
S.M., Carlotti, C.G., Caballero, O.L., Simpson, A.J., 2006. PIK3CA gene mutations in
pediatric and adult glioblastoma multiforme. Mol. Cancer Res. 4, 709–714.
Guessous, F., Zhang, Y., Kofman, A., Catania, A., Li, Y., Schiff, D., Purow, B., Abounader,
R., 2010. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.
Cell Cycle 9, 1031–1036.
Guo, Y., Yan, K., Fang, J., Qu, Q., Zhou, M., Chen, F., 2013. Let-7b expression determines
response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J.
Exp. Clin. Cancer Res. 32, 41.
Hambardzumyan, D., Bergers, G., 2015. Glioblastoma: defining tumor niches. Trends
Cancer 1, 252–265.
Hambardzumyan, D., Gutmann, D.H., Kettenmann, H., 2016. The role of microglia and
macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20–27.
Hasmim, M., Bruno, S., Azzi, S., Gallerne, C., Michel, J.G., Chiabotto, G., Lecoz, V.,
Romei, C., Spaggiari, G.M., Pezzolo, A., Pistoia, V., Angevin, E., Gad, S., Ferlicot, S.,
Messai, Y., Kieda, C., Clay, D., Sabatini, F., Escudier, B., Camussi, G., Eid, P.,
Azzarone, B., Chouaib, S., 2016. Isolation and characterization of renal cancer stem
cells from patient-derived xenografts. Oncotarget 7, 15507–15524.
He, J., Zhang, W., Zhou, Q., Zhao, T., Song, Y., Chai, L., Li, Y., 2013. Low-expression of
microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int. J.
Biochem. Cell Biol. 45, 1962–1973.
Herman, J.G., Baylin, S.B., 2003. Gene silencing in cancer in association with promoter
hypermethylation. N. Engl. J. Med. 349, 2042–2054.
Hiddingh, L., Tannous, B.A., Teng, J., Tops, B., Jeuken, J., Hulleman, E., Boots-Sprenger,
S.H., Vandertop, W.P., Noske, D.P., Kaspers, G.J., Wesseling, P., Wurdinger, T., 2014.
EFEMP1 induces gamma-secretase/Notch-mediated temozolomide resistance in
glioblastoma. Oncotarget 5, 363–374.
Hirano, H., Tanioka, K., Yokoyama, S., Akiyama, S.-i., Kuratsu, J.-i., 2001. Angiogenic
effect of thymidine phosphorylase on macrophages in glioblastoma multiforme. J.
Neurosurg. 95, 89–95.
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A.,
Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B.D., Hoshyar, R., Seyfoori, A.,
Sepehri, Z., Ande, S.R., Khadem, F., Akbari, M., Gorman, A.M., Samali, A., Klonisch,
T., Ghavami, S., 2017. Glioblastoma and chemoresistance to alkylating agents: in-
volvement of apoptosis, autophagy, and unfolded protein response. Pharmacol. Ther.
Honorato, J., de Faria Lopes, G.P., Basile, G., Moura-Neto, V., Spohr, T., 2018. Sonic
Hedgehog Inhibition in Glioblastoma Potentializes Temozolomide Effect? CLINICAL
CANCER RESEARCH, AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH
FLOOR, PHILADELPHIA, PA 19106-4404 USA, pp. 91.
Hu, B., Wang, Q., Wang, Y.A., Hua, S., Sauvé, C.-E.G., Ong, D., Lan, Z.D., Chang, Q., Ho,
Y.W., Monasterio, M.M., 2016. Epigenetic activation of WNT5A drives glioblastoma
stem cell differentiation and invasive growth. Cell 167, 1281–1295 e1218.
Huang, S.-M.A., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A., Charlat,
O., Wiellette, E., Zhang, Y., Wiessner, S., 2009. Tankyrase inhibition stabilizes axin
and antagonizes Wnt signalling. Nature 461, 614–620.
Iacopino, F., Angelucci, C., Piacentini, R., Biamonte, F., Mangiola, A., Maira, G., Grassi,
C., Sica, G., 2014. Isolation of cancer stem cells from three human glioblastoma cell
lines: characterization of two selected clones. PLoS One 9, e105166.
Ishii, A., Kimura, T., Sadahiro, H., Kawano, H., Takubo, K., Suzuki, M., Ikeda, E., 2016.
Histological characterization of the tumorigenic “Peri-Necrotic Niche” harboring
quiescent stem-like tumor cells in glioblastoma. PLoS One 11 e0147366.
Jackson, M., Hassiotou, F., Nowak, A., 2014. Glioblastoma stem-like cells: at the root of
tumor recurrence and a therapeutic target. Carcinogenesis p. bgu243.
Jangamreddy, J.R., Ghavami, S., Grabarek, J., Kratz, G., Wiechec, E., Fredriksson, B.A.,
Rao Pariti, R.K., Cieslar-Pobuda, A., Panigrahi, S., Los, M.J., 2013. Salinomycin in-
duces activation of autophagy, mitophagy and affects mitochondrial polarity: dif-
ferences between primary and cancer cells. Biochim. Biophys. Acta 1833, 2057–2069.
Jangamreddy, J.R., Jain, M.V., Hallbeck, A.L., Roberg, K., Lotfi, K., Los, M.J., 2015.
Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies
cancer cell specific cell death. Oncotarget 6, 10134–10145.
Kalani, M.Y.S., Cheshier, S.H., Cord, B.J., Bababeygy, S.R., Vogel, H., Weissman, I.L.,
Palmer, T.D., Nusse, R., 2008. Wnt-mediated self-renewal of neural stem/progenitor
cells. Proc. Natl. Acad. Sci. 105, 16970–16975.
Kaloshi, G., Mokhtari, K., Carpentier, C., Taillibert, S., Lejeune, J., Marie, Y., Delattre, J.-
Y., Godbout, R., Sanson, M., 2007. FABP7 expression in glioblastomas: relation to
prognosis, invasion and EGFR status. J. Neurooncol. 84, 245–248.
Kaneko, Y., Sakakibara, S., Imai, T., Suzuki, A., Nakamura, Y., Sawamoto, K., Ogawa, Y.,
Toyama, Y., Miyata, T., Okano, H., 2000. Musashi1: an evolutionally conserved
marker for CNS progenitor cells including neural stem cells. Dev. Neurosci. 22,
139–153.
Kardosh, A., Golden, E.B., Pyrko, P., Uddin, J., Hofman, F.M., Chen, T.C., Louie, S.G.,
Petasis, N.A., Schönthal, A.H., 2008. Aggravated endoplasmic reticulum stress as a
basis for enhanced glioblastoma cell killing by bortezomib in combination with cel-
ecoxib or its non-coxib analogue, 2, 5-dimethyl-celecoxib. Cancer Res. 68, 843–851.
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y.T., Kim, H., Rheey, J.,
Nakano, I., 2013. Phosphorylation of EZH2 activates STAT3 signaling via STAT3
methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell
23, 839–852.
Kohanbash, G., Okada, H., 2012. Myeloid-derived suppressor cells (MDSCs) in gliomas
and glioma-development. Immunol. Invest. 41, 658–679.
Koppens, M., Van Lohuizen, M., 2016. Context-dependent actions of Polycomb repressors
in cancer. Oncogene 35, 1341–1352.
Koschmann, C., Zamler, D., MacKay, A., Robinson, D., Wu, Y.-M., Doherty, R., Marini, B.,
Tran, D., Garton, H., Muraszko, K., 2016. Characterizing and Targeting PDGFRA
Alterations in Pediatric High-grade Glioma.
Lathia, J.D., Liu, H., 2017. Overview of Cancer stem cells and stemness for community
oncologists. Target. Oncol. 12, 387–399.
Lee, Y., Kim, K.H., Kim, D.G., Cho, H.J., Kim, Y., Rheey, J., Shin, K., Seo, Y.J., Choi, Y.-S.,
Lee, J.-I., 2015. FoxM1 promotes stemness and radio-resistance of glioblastoma by
regulating the master stem cell regulator Sox2. PLoS One 10, e0137703.
Lee, Y., Lee, J.-K., Ahn, S.H., Lee, J., Nam, D.-H., 2016. WNT signaling in glioblastoma
and therapeutic opportunities. Lab. Investig. 96, 137–150.
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L.,
Jiang, J., Yang, Y., Schmittgen, T.D., 2009. MicroRNA-34a inhibits glioblastoma
growth by targeting multiple oncogenes. Cancer Res. 69, 7569–7576.
Li, W., Zhang, H., Assaraf, Y.G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., Chen, Z.-S., 2016.
Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms
and novel therapeutic drug strategies. Drug Resist. Updates 27, 14–29.
Liang, J., Piao, Y., Holmes, L., Fuller, G.N., Henry, V., Tiao, N., de Groot, J.F., 2014.
Neutrophils promote the malignant glioma phenotype through S100A4. Clin. Cancer
Res. 20, 187–198.
Liao, H., Bai, Y., Qiu, S., Zheng, L., Huang, L., Liu, T., Wang, X., Liu, Y., Xu, N., Yan, X.,
2015. MiR-203 downregulation is responsible for chemoresistance in human glio-
blastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6,
8914.
Liu, Y., Yan, W., Zhang, W., Chen, L., You, G., Bao, Z., Wang, Y., Wang, H., Kang, C.,
Jiang, T., 2012. MiR-218 reverses high invasiveness of glioblastoma cells by targeting
the oncogenic transcription factor LEF1. Oncol. Rep. 28, 1013–1021.
Livney, Y.D., Assaraf, Y.G., 2013. Rationally designed nanovehicles to overcome cancer
chemoresistance. Adv. Drug Deliv. Rev. 65, 1716–1730.
Lv, Z., Yang, L., 2013. MiR-124 inhibits the growth of glioblastoma through the down-
regulation of SOS1. Mol. Med. Rep. 8, 345–349.
Ma, Y., Yu, W., Shrivastava, A., Alemi, F., Lankachandra, K., Srivastava, R.K., Shankar, S.,
2017. Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing
oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway. Carcinogenesis
38, 1047–1056.
Mack, S.C., Hubert, C.G., Miller, T.E., Taylor, M.D., Rich, J.N., 2016. An epigenetic
gateway to brain tumor cell identity. Nat. Neurosci. 19, 10–19.
Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., 2002. Macrophage polar-
ization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear
phagocytes. Trends Immunol. 23, 549–555.
Mathew, L.K., Skuli, N., Mucaj, V., Lee, S.S., Zinn, P.O., Sathyan, P., Imtiyaz, H.Z., Zhang,
Z., Davuluri, R.V., Rao, S., 2014. miR-218 opposes a critical RTK-HIF pathway in
mesenchymal glioblastoma. Proc. Natl. Acad. Sci. 111, 291–296.
Mathiisen, T.M., Lehre, K.P., Danbolt, N.C., Ottersen, O.P., 2010. The perivascular
F. Sharifzad, et al. Drug Resistance Updates 42 (2019) 35–45
43
astroglial sheath provides a complete covering of the brain microvessels: an electron
microscopic 3D reconstruction. Glia 58, 1094–1103.
Mazzoleni, S., Politi, L.S., Pala, M., Cominelli, M., Franzin, A., Sergi, L.S., Falini, A., De
Palma, M., Bulfone, A., Poliani, P.L., 2010. Epidermal growth factor receptor ex-
pression identifies functionally and molecularly distinct tumor-initiating cells in
human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 70,
7500–7513.
McCord, A.M., Jamal, M., Williams, E.S., Camphausen, K., Tofilon, P.J., 2009. CD133+
glioblastoma stem-like cells are radiosensitive with a defective DNA damage response
compared with established cell lines. Clin. Cancer Res. 15, 5145–5153.
McLendon, R., Friedman, A., Bigner, D., Van Meir, E.G., Brat, D.J., Mastrogianakis, G.M.,
Olson, J.J., Mikkelsen, T., Lehman, N., Aldape, K., 2008. Comprehensive genomic
characterization defines human glioblastoma genes and core pathways. Nature 455,
1061–1068.
Mengxian, Z., Kleber, S., Roehrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-
Villalba, A., Debus, J., Peschke, P., Wirkner, U., 2011. Blockade of TGF-beta signaling
by the TGFβR-I kinase Inhibitor LY2109761 enhances radiation response and pro-
longs survival in glioblastoma. Cancer Res p. canres. 1212.2011.
Møller, H.G., Rasmussen, A.P., Andersen, H.H., Johnsen, K.B., Henriksen, M., Duroux, M.,
2013. A systematic review of microRNA in glioblastoma multiforme: micro-mod-
ulators in the mesenchymal mode of migration and invasion. Mol. Neurobiol. 47,
131–144.
Nagarajan, R.P., Costello, J.F., 2009. Epigenetic mechanisms in glioblastoma multiforme.
Seminars in Cancer Biology. Elsevier, pp. 188–197.
Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P.,
Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., 2010. Identification of a CpG island
methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17,
510–522.
Ogden, A.T., Waziri, A.E., Lochhead, R.A., Fusco, D., Lopez, K., Ellis, J.A., Kang, J.,
Assanah, M., McKhann, G.M., Sisti, M.B., 2008. Identification of A2B5+ CD133−
tUMOR-iNITIATING cells in adult human GLIOMAS. Neurosurgery 62, 505–515.
Papagiannakopoulos, T., Friedmann-Morvinski, D., Neveu, P., Dugas, J., Gill, R., Huillard,
E., Liu, C., Zong, H., Rowitch, D., Barres, B., 2012. Pro-neural miR-128 is a glioma
tumor suppressor that targets mitogenic kinases. Oncogene 31, 1884–1895.
Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.-H., Leary, R.J., Angenendt, P., Mankoo, P.,
Carter, H., Siu, I.-M., Gallia, G.L., 2008. An integrated genomic analysis of human
glioblastoma multiforme. Science 321, 1807–1812.
Piccirillo, S., Reynolds, B.A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H.,
Olivi, A., Dimeco, F., Vescovi, A.L., 2006. Bone morphogenetic proteins inhibit the
tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761–765.
Pietras, A., Katz, A.M., Ekström, E.J., Wee, B., Halliday, J.J., Pitter, K.L., Werbeck, J.L.,
Amankulor, N.M., Huse, J.T., Holland, E.C., 2014. Osteopontin-CD44 signaling in the
glioma perivascular niche enhances cancer stem cell phenotypes and promotes ag-
gressive tumor growth. Cell Stem Cell 14, 357–369.
Plaks, V., Kong, N., Werb, Z., 2015. The cancer stem cell niche: how essential is the niche
in regulating stemness of tumor cells? Cell Stem Cell 16, 225–238.
Pointer, K.B., Clark, P.A., Zorniak, M., Alrfaei, B.M., Kuo, J.S., 2014. Glioblastoma cancer
stem cells: biomarker and therapeutic advances. Neurochem. Int. 71, 1–7.
Prestegarden, L., Svendsen, A., Wang, J., Sleire, L., Skaftnesmo, K.O., Bjerkvig, R., Yan, T.,
Askland, L., Persson, A., Sakariassen, P.Ø., 2010. Glioma cell populations grouped by
different cell type markers drive brain tumor growth. Cancer Res. 70, 4274–4279.
Pulvirenti, T., Van Der Heijden, M., Droms, L.A., Huse, J.T., Tabar, V., Hall, A., 2011.
Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas.
Cancer Res. 71, 7280–7290.
Qian, B.-Z., Pollard, J.W., 2010. Macrophage diversity enhances tumor progression and
metastasis. Cell 141, 39–51.
Richardson, P.J., 2016. CXCR4 and glioblastoma, Anti-Cancer Agents in Medicinal
Chemistry. Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 16, 59–74.
Rivera, L.B., Bergers, G., 2015. Intertwined regulation of angiogenesis and immunity by
myeloid cells. Trends Immunol. 36, 240–249.
Rizzino, A., 2009. Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate
the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip. Rev.
Syst. Biol. Med. 1, 228–236.
Rooj, A.K., Mineo, M., Ricklefs, F., Bronisz, A., Chiocca, E., Godlewski, J., 2016. The
Novel Role of microRNA-128 in Proneural to Mesenchymal Subtype Transition in
Glioblastoma Stem Cells by Targeting Components of Pro-oncogenic Polycomb
Repressor Complex. AACR.
Safa, A.R., Saadatzadeh, M.R., Cohen-Gadol, A.A., Pollok, K.E., Bijangi-Vishehsaraei, K.,
2015. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion be-
tween differentiated non-GSCs and GSCs. Genes Dis. 2, 152–163.
Saito, N., Aoki, K., Hirai, N., Fujita, S., Iwama, J., Ikota, M., Nakayama, H., Hayashi, M.,
Ito, K., Sakurai, T., 2017. Notch Pathway Activation Predicts Resistance to
Bevacizumab Therapy in Glioblastoma. AACR.
Samatov, T.R., Wicklein, D., Tonevitsky, A.G., 2016. L1CAM: cell adhesion and more.
Prog. Histochem. Cytochem. 51, 25–32.
Sareddy, G.R., Kesanakurti, D., Kirti, P.B., Babu, P.P., 2013. Nonsteroidal anti-in-
flammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling
pathway in human glioblastoma cells. Neurochem. Res. 38, 2313–2322.
Sarkar, S., Mirzaei, R., Zemp, F.J., Wei, W., Senger, D.L., Robbins, S.M., Yong, V.W., 2017.
Activation of NOTCH signaling by Tenascin-C promotes growth of human brain
tumor-initiating cells. Cancer Res. 77, 3231–3243.
Schito, L., Semenza, G.L., 2016. Hypoxia-inducible factors: master regulators of cancer
progression. Trends Cancer 2, 758–770.
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D.T., Pfaff, E., Jacob, K., Sturm, D.,
Fontebasso, A.M., Quang, D.-A.K., Tönjes, M., 2012. Driver mutations in histone H3.
3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226–231.
Seidel, S., Garvalov, B.K., Wirta, V., von Stechow, L., Schänzer, A., Meletis, K., Wolter, M.,
Sommerlad, D., Henze, A.-T., Nistér, M., 2010. A hypoxic niche regulates glio-
blastoma stem cells through hypoxia inducible factor 2α. Brain 133, 983–995.
Semenza, G.L., 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and
therapeutics. Oncogene 29, 625–634.
Shahi, M.H., Farheen, S., Mariyath, M.P., Castresana, J.S., 2016. Potential role of Shh-
Gli1-BMI1 signaling pathway nexus in glioma chemoresistance. Tumour Biol. 37,
15107–15114.
Silver, D.J., Lathia, J.D., 2017. Revealing the glioma Cancer stem cell interactome, one
niche at a time. J. Pathol.
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., Dirks, P.B.,
2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63,
5821–5828.
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M.,
Cusimano, M.D., Dirks, P.B., 2004. Identification of human brain tumour initiating
cells. nature 432, 396–401.
Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H.,
Pastorino, S., Yang, M., Hoffman, R.M., Kesari, S., 2011. Transdifferentiation of
glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. 108,
4274–4280.
Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R., Engh, J.,
Iwama, T., Kunisada, T., Kassam, A., 2009. Hypoxia promotes expansion of the
CD133-positive glioma stem cells through activation of HIF-1α. Oncogene 28,
3949–3959.
Soehngen, E., Schaefer, A., Koeritzer, J., Huelsmeyer, V., Zimmer, C., Ringel, F., Gempt,
J., Schlegel, J., 2014. Hypoxia upregulates aldehyde dehydrogenase isoform 1
(ALDH1) expression and induces functional stem cell characteristics in human glio-
blastoma cells. Brain Tumor Pathol. 31, 247–256.
Son, M.J., Woolard, K., Nam, D.-H., Lee, J., Fine, H.A., 2009. SSEA-1 is an enrichment
marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4, 440–452.
Speranza, M.C., Frattini, V., Pisati, F., Kapetis, D., Porrati, P., Eoli, M., Pellegatta, S.,
Finocchiaro, G., 2012. NEDD9, a novel target of miR-145, increases the invasiveness
of glioblastoma. Oncotarget 3, 723–734.
Sun, H., Zhang, M., Cheng, K., Li, P., Han, S., Li, R., Su, M., Zeng, W., Liu, J., Guo, J.,
2016. Resistance of glioma cells to nutrient-deprived microenvironment can be en-
hanced by CD133-mediated autophagy. Oncotarget 7, 76238.
Tessarz, P., Kouzarides, T., 2014. Histone core modifications regulating nucleosome
structure and dynamics. Nat. Rev. Mol. Cell Biol. 15, 703–708.
Thanasupawat, T., Natarajan, S., Rommel, A., Glogowska, A., Bergen, H., Krcek, J., Pitz,
M., Beiko, J., Krawitz, S., Verma, I.M., 2017. Dovitinib enhances temozolomide ef-
ficacy in glioblastoma cells. Mol. Oncol.
Tome-Garcia, J., Tejero, R., Nudelman, G., Yong, R.L., Sebra, R., Wang, H., Fowkes, M.,
Magid, M., Walsh, M., Silva-Vargas, V., 2017. Prospective isolation and comparison
of human germinal matrix and glioblastoma EGFR+ populations with stem cell
properties. Stem Cell Rep. 8, 1421–1429.
Torre-Healy, L.A., Berezovsky, A., Lathia, J.D., 2017. Isolation, characterization, and
expansion of cancer stem cells. Adult Stem Cells: Methods Protocols 133–143.
Uribe, D., Torres, Á., Rocha, J.D., Niechi, I., Oyarzún, C., Sobrevia, L., San Martín, R.,
Quezada, C., 2017. Multidrug resistance in glioblastoma stem-like cells: role of the
hypoxic microenvironment and adenosine signaling. Mol. Aspects Med. 140–151.
Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R.,
Ding, L., Golub, T., Mesirov, J.P., 2010. Integrated genomic analysis identifies
clinically relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110.
Wang, C.-H., Chiou, S.-H., Chou, C.-P., Chen, Y.-C., Huang, Y.-J., Peng, C.-A., 2011.
Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes con-
jugated with CD133 monoclonal antibody. Nanomed. Nanotechnol. Biol. Med. 7,
69–79.
Wang, J., Wang, C., Meng, Q., Li, S., Sun, X., Bo, Y., Yao, W., 2012. siRNA targeting
Notch-1 decreases glioma stem cell proliferation and tumor growth. Mol. Biol. Rep.
39, 2497–2503.
Wang, X.-R., Luo, H., Li, H.-L., Cao, L., Wang, X.-F., Yan, W., Wang, Y.-Y., Zhang, J.-X.,
Jiang, T., Kang, C.-S., 2013. Overexpressed let-7a inhibits glioma cell malignancy by
directly targeting K-ras, independently of PTEN. Neurooncology 15, 1491–1501.
Wasik, A.M., Grabarek, J., Pantovic, A., Cieslar-Pobuda, A., Asgari, H.R., Bundgaard-
Nielsen, C., Rafat, M., Dixon, I.M., Ghavami, S., Los, M.J., 2014. Reprogramming and
carcinogenesis–parallels and distinctions. Int. Rev. Cell Mol. Biol. 308, 167–203.
Wee, B., Pietras, A., Ozawa, T., Bazzoli, E., Podlaha, O., Antczak, C., Westermark, B.,
Nelander, S., Uhrbom, L., Forsberg-Nilsson, K., 2016. ABCG2 regulates self-renewal
and stem cell marker expression but not tumorigenicity or radiation resistance of
glioma cells. Sci. Rep. 6.
Wickström, M., Dyberg, C., Milosevic, J., Einvik, C., Calero, R., Sveinbjörnsson, B.,
Sandén, E., Darabi, A., Siesjö, P., Kool, M., 2015. Wnt/β-catenin pathway regulates
MGMT gene expression in cancer and inhibition of Wnt signalling prevents che-
moresistance. Nat. Commun. 6.
Witt, A., Lee, C., Lee, T., Azzam, D., Wang, B., Caslini, C., Petrocca, F., Grosso, J., Jones,
M., Cohick, E., 2016. Identification of a cancer stem cell-specific function for the
histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene.
Xia, H., Cheung, W.K., Ng, S.S., Jiang, X., Jiang, S., Sze, J., Leung, G.K., Lu, G., Chan, D.T.,
Bian, X.-W., 2012. Loss of brain-enriched miR-124 microRNA enhances stem-like
traits and invasiveness of glioma cells. J. Biol. Chem. 287, 9962–9971.
Xipell, E., Gonzalez-Huarriz, M., Martinez de Irujo, J.J., Garcia-Garzon, A., Lang, F.F.,
Jiang, H., Fueyo, J., Gomez-Manzano, C., Alonso, M.M., 2016. Salinomycin induced
ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma.
Oncotarget 7, 30626–30641.
Xu, Y., Stamenkovic, I., Yu, Q., 2010. CD44 attenuates activation of the hippo signaling
F. Sharifzad, et al. Drug Resistance Updates 42 (2019) 35–45
44
pathway and is a prime therapeutic target for glioblastoma. Cancer research 70,
2455–2464.
Xu, J., Liao, X., Lu, N., Liu, W., Wong, C.W., 2011. Chromatin-modifying drugs induce
miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines. Int. J. Cancer 129,
2527–2531.
Yi, G.-z., Liu, Y.-w., Xiang, W., Wang, H., Chen, Z.-y., Qi, S.-t., 2016. Akt and β-catenin
contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
J. Neurol. Sci. 367, 101–106.
Zagzag, D., Lukyanov, Y., Lan, L., Ali, M.A., Esencay, M., Mendez, O., Yee, H., Voura, E.B.,
Newcomb, E.W., 2006. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in
glioblastoma: implications for angiogenesis and glioma cell invasion. Lab. Investig.
86, 1221–1232.
Zbinden, M., Duquet, A., Lorente-Trigos, A., Ngwabyt, S.N., Borges, I., i Altaba, A.R.,
2010. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-
functional network with GLI1 and p53. EMBO J. 29, 2659–2674.
Zhang, Y., Chao, T., Li, R., Liu, W., Chen, Y., Yan, X., Gong, Y., Yin, B., Qiang, B., Zhao, J.,
2009. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription
factor E2F3a. J. Mol. Med. 87, 43–51.
Zhang, J., Sun, C., Yu, S., Wang, Q., An, T., Li, Y., Kong, Y., Wen, Y., 2011. Relationship
between miR-218 and CDK6 expression and their biological impact on glioma cell
proliferation and apoptosis. Zhonghua bing li xue za zhi Chin. J. Pathol. 40, 454–459.
Zhang, Y., Kim, J., Mueller, A., Dey, B., Yang, Y., Lee, D., Hachmann, J., Finderle, S., Park,
D., Christensen, J., 2014. Multiple receptor tyrosine kinases converge on microRNA-
134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differ. 21, 720–734.
Zhao, S., Deng, Y., Liu, Y., Chen, X., Yang, G., Mu, Y., Zhang, D., Kang, J., Wu, Z., 2013.
MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol. Biol. Rep. 40,
2789–2798.
Zhao, H.-f., Wang, J., Shao, W., Wu, C.-p., Chen, Z.-p., To, S.-s.T., Li, W.-p., 2017. Recent
advances in the use of PI3K inhibitors for glioblastoma multiforme: current pre-
clinical and clinical development. Mol. Cancer 16, 100.
Zheng, H., Ying, H., Yan, H., Kimmelman, A.C., Hiller, D.J., Chen, A.-J., Perry, S.R.,
Tonon, G., Chu, G.C., Ding, Z., 2008. p53 and Pten control neural and glioma stem/
progenitor cell renewal and differentiation. Nature 455, 1129–1133.
Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S.N., Ivanova, E.V., Paik, J.-H.,
Zhang, H., Xiao, Y., Perry, S.R., 2010. PLAGL2 regulates Wnt signaling to impede
differentiation in neural stem cells and gliomas. Cancer Cell 17, 497–509.
Zhou, W., Ke, S.Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A.E.,
McLendon, R.E., Li, X., 2015a. Periostin secreted by glioblastoma stem cells recruits
M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol.
17, 170–182.
Zhou, W., Ke, S.Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A.E.,
McLendon, R.E., Li, X., Rich, J.N., Bao, S., 2015b. Periostin secreted by glioblastoma
stem cells recruits M2 tumour-associated macrophages and promotes malignant
growth. Nat. Cell Biol. 17, 170–182.
Zhu, Y., Yu, T., Zhang, X.-C., Nagasawa, T., Wu, J.Y., Rao, Y., 2002. Role of the che-
mokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat.
Neurosci. 5, 719–720.
Zuccarini, M., Giuliani, P., Ziberi, S., Carluccio, M., Iorio, P.D., Caciagli, F., Ciccarelli, R.,
2018. The role of wnt signal in glioblastoma development and progression: a possible
new pharmacological target for the therapy of this tumor. Genes 9, 105.
F. Sharifzad, et al. Drug Resistance Updates 42 (2019) 35–45
45
